Piramal Pharma Ltd: Piramal Pharma Limited Announces Results for Q3 and 9M FY25
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today ...
Piramal Pharma Limited Announces Results for Q3 and 9M FY25
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...
AbbVie Inc. stock outperforms competitors despite losses on the day
AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.
A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...
AbbVie price target lowered to $205 from $215 at Citi
Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...
AbbVie's SWOT analysis: biopharma giant navigates post-Humira landscape
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...
Why AbbVie Stock Popped While the Market Flopped on Monday
Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...
Merck KGaA says high asset prices call for prudent M&A approach
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious ...
AbbVie completes acquisition of Nimble Therapeutics
AbbVie (ABBV) announced that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a ...